Omeros Corp (OMER) · Oct 30, 2026 · Other events
Performance option grant — Four hurdles: $25, $30, $35 and $40
Omeros filed an executive compensation grant for Gregory Demopulos with four stock-price hurdles, adding alignment but leaving dilution unclear.
Omeros is moving from development-stage biotech toward commercial execution around YARTEMLEA, its FDA-approved treatment for transplant-associated thrombotic microangiopathy, while advancing additional complement, oncology and addiction programs. The filing puts CEO Gregory A. Demopulos on a performance-based equity plan. The exercise notice identifies Demopulos as the purchaser, and the option is split into four equal tranches tied to 30-trading-day VWAP hurdles of $25, $30, $35 and $40. 〔0〕
The structure is meaningfully performance-linked, but not a clean near-term operating signal. Each tranche requires continued service and vests gradually over four years—25% after the first anniversary, then monthly—so the award is designed to retain management and tie part of its value to sustained shareholder performance rather than simply handing over immediately exercisable equity.
The main limitation is missing scale. The supplied filing content does not state the number of option shares or the exercise price, so investors cannot quantify potential dilution or the award’s economic value from this disclosure alone. The filing also provides change-in-control treatment: hurdles are deemed satisfied only for tranches matching consideration of at least the relevant threshold, while lower-value tranches are forfeited.
Bottom line: This is a new alignment and retention mechanism for Omeros’ CEO, not a change to the company’s operating outlook. It is mildly constructive in design, but the undisclosed grant size keeps the economic impact—and any dilution concern—uncertain.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!